<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090089</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XIII</org_study_id>
    <nct_id>NCT01090089</nct_id>
  </id_info>
  <brief_title>Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma</brief_title>
  <acronym>DSM XIII</acronym>
  <official_title>The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until
      progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m²
      augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before
      transplantation and lenalidomide maintenance after transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2010</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 yrs</time_frame>
    <description>To compare the efficacy of both treatment regimens with regard to progression-free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 yrs</time_frame>
    <description>To assess the safety and overall survival of both treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Response (complete response [CR], stringent complete response [sCR], very good partial response [VGPR], partial response [PR] and overall response [CR (incl. sCR)+ VGPR + PR]) according to IMWG criteria</measure>
    <time_frame>5 yrs</time_frame>
    <description>To investigate other efficacy parameters of both treatment regimens</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">348</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomid, PBSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Dexamethasone</intervention_name>
    <description>Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)</description>
    <arm_group_label>Lenalidomid</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Dexamethasone, PBSCT</intervention_name>
    <description>Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years</description>
    <arm_group_label>Lenalidomid, PBSCT</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Understand and voluntarily sign an informed consent form. 2. Age 60-75 years at the time
        of signing the informed consent form. 3. Able to adhere to the study visit schedule and
        other protocol requirements. 4. Symptomatic MM requiring therapy. 5. Measurable monoclonal
        protein in serum and/or urine 6. Monoclonal plasma cells in the bone marrow &gt;/= 10% and/or
        biopsy-proven plasmacytoma 7. Myeloma-related organ dysfunction, at least one of [C]
        Calcium elevation in the serum (&gt; 11.5 mg/dL or &gt; 2.65 mmol/l) [R] Renal insufficiency
        (creatinine &gt; 173 μmol/l or &gt; 2 mg/dL) [A] Anemia (Hb &lt; 10 g/dL or 2 g/dL &lt; normal) [B]
        Bone lesions or general osteoporosis 8. ECOG PS of &lt;/= 2 ... 9. Laboratory test results
        within these ranges within 1 week prior to randomization:

          -  ANC &gt;/= 1.0 x 109/L.

          -  Platelet count &gt;/= 75 x 109/L or in case of bone marrow infiltration with myeloma
             cells &gt;/= 30 x 109/L.

          -  Total bilirubin &lt;/= 2 mg/dL.

          -  AST (SGOT) and ALT (SGPT) &lt;/= 3 x ULN. 8. Female subjects of childbearing potential
             must: o Understand the study drug is expected to have a teratogenic risk

             o Agree to use, ..., effective contraception without interruption,...

             o Understand that even if she has amenorrhea, she must follow all the advice on
             effective contraception.

             o She understands the potential consequences of pregnancy and the need to rapidly
             consult if there is a risk of pregnancy

             o Agree to have a medically supervised pregnancy test ...

          -  Male subjects must

             o Agree to use condoms throughout study drug therapy, during any dose interruption and
             for one week after cessation of study drug therapy ...

               -  Agree not to donate semen during study drug therapy and for one week after end of
                  study drug therapy.

          -  All subjects must

               -  Agree to abstain from donating blood while taking study drug therapy and for one
                  week following discontinuation of study drug therapy.

               -  Agree not to share study drug with another person and to return all unused study
                  drug to the investigator.

                  9. Disease free of prior malignancies for &gt;/= 5 years with exception of currently
                  treated basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot;
                  of the cervix or breast.

                  10. Able to receive antithrombotic prophylaxis (...). 11. Life-expectancy &gt; 3
                  months.

        Exclusion Criteria:

          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the ICF.

          2. Pregnant or lactating females

          3. Any condition, incl. the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          4. Patient currently is enrolled in another clinical research study or has been enrolled
             ...within 4 weeks before randomization and/or is receiving an investigational agent
             for any reason ...

          5. Known hypersensitivity to thalidomide, dexamethasone, or melphalan.

          6. The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          7. Any prior use of lenalidomide.

          8. Concurrent use of other anti-cancer agents or treatments.

          9. Known positive for HIV or active infectious hepatitis, type A, B or C or treponema
             pallidum

         10. Prior treatment with dexamethasone discontinued because of ≥ grade 3
             dexamethasone-related toxicity.

         11. Any prior chemotherapy with the exception of a short course of dexamethasone more than
             4 weeks before randomization.

         12. Immunotherapy or antibody therapy within 8 weeks before randomization.

         13. Major surgery within 4 weeks before randomization.

         14. Renal failure requiring dialysis.

         15. Myocardial infarction within 6 months before randomization, NYHA Class III or IV heart
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities.

         16. Severe pulmonary disease (diffusion capacity &lt; 60% of normal).

         17. Treatment for cancer other than MM within 5 years before randomization, with the
             exception of basal cell carcinoma or cervical cancer in situ.

         18. Cardiac amyloidosis.

         19. Poorly controlled hypertension, diabetes mellitus, or other serious medical or
             psychiatric illness that could potentially interfere with the completion of treatment
             according to the protocol.

         20. Any systemic infection requiring treatment.

         21. Unability or unwillingness of the patient to receive antithrombotic prophylaxis.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Straka</last_name>
    <role>Principal Investigator</role>
    <affiliation>Agirov Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Muenster</city>
        <state>North Rhein Westfallen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agirov Klinik</name>
      <address>
        <city>Berg</city>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald -Anstalt öffentlichen Rechts-</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein gGmbH</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut gemeinnützige GmbH</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Schwerpunktpraxis</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Elisenhof</name>
      <address>
        <city>München</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum München Harlaching</name>
      <address>
        <city>München</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann gGmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Innere Medizin, Hämatologie und Onkologie</name>
      <address>
        <city>Ravensburg</city>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart-Diakonissenkrankenhaus und Paulinenhilfe gGmbH</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSK Dr. Horst-Schmidt-Kliniken gmbh</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

